| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. | Anticancer Drugs | 2001 | 1.22 |
| 2 | Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. | Ann Oncol | 1994 | 1.00 |
| 3 | Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. | Br J Cancer | 1997 | 0.95 |
| 4 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. | Br J Cancer | 1999 | 0.87 |
| 5 | High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. | Semin Oncol | 1995 | 0.79 |
| 6 | Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer. | Br J Cancer | 2013 | 0.76 |